Told you! Just traded as low as 61. Until Zerbe gives more realistic and confidant profit guidance this gets played. He's had the same Forfivo guidance for almost 2 years, even though they no longer have any generic competition and have the only single dose 450mg product. Current guidance shows only 6-7% marketplace penetration. With the advantages Forfivo has the guidance should be at least double that.
big news? on the way? no i am not buying for a quick buck here, nor do i believe you, should i?
I am in as i know the potential of the company in the long term, i expect a double in 2 years (being conservative)